Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.55 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010738 | 0.85 | SMN1; SMN2 (1.00) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL4300704 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL17241116 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL13265505 | 0.83 | SMN1; SMN2 (0.71) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL23909056 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL30151141 | 0.81 | LMNA (1.00) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL5717747 | 0.81 | LMNA (1.00) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL4931969 | 0.80 | LMNA (0.73) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E | |
| SCHEMBL23909017 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL4817305 | 0.79 | PRMT5 (0.68) | SMN1; SMN2ALDH1A1LMNAPOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3649119-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GALAPAGOS NV (BE) | 2021-11-03 | — | — | EP | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
| CN-110869359-A | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | 加拉帕戈斯股份有限公司 | 2020-03-06 | — | — | CN | disclosed |
| US-20170216292-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-03 | — | — | US | disclosed |
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-08-03 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| US-5304557-A | Aldose reductase inhibitor | PFIZER INC. (US) | 1994-04-19 | — | — | US | disclosed |
| EP-0436307-A1 | Substituted oxophthalazinyl acetic acids and analogs thereof | PFIZER INC. (US) | 1991-07-10 | — | — | EP | disclosed |
| WO-1991009019-A1 | SUBSTITUTED OXOPHTHALAZINYL ACETIC ACIDS AND ANALOGS THEREOF | PFIZER INC. (US) | 1991-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216291-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20170216292-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | SMN1; SMN2 2204/4885ALDH1A1 18/4885LMNA 1361/4885 |
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885ALDH1A1 944/4885LMNA 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.